BridgeBio Pharma (BBIO) Operating Leases (2020 - 2026)

BridgeBio Pharma has disclosed Operating Leases across 7 years of filings, most recently posting $18.7 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $18.7 million, up 279.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.7 million (up 279.55% YoY), and the FY2025 annual result was $3.8 million, down 18.85% from the prior year.
• Operating Leases came in at $18.7 million for Q1 2026 at BridgeBio Pharma, up from $3.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.7 million in Q1 2026 to a low of $3.4 million in Q3 2025.
• The 5-year median for Operating Leases is $9.0 million (2023), against an average of $9.3 million.
• Across the five-year window, Operating Leases sank 47.71% in 2024 and jumped 279.55% in 2026, its largest moves.
• BridgeBio Pharma's Operating Leases stood at $12.3 million in 2022, then declined by 26.83% to $9.0 million in 2023, then sank by 47.71% to $4.7 million in 2024, then declined by 18.85% to $3.8 million in 2025, then jumped by 389.5% to $18.7 million in 2026.
• The last three Operating Leases figures came in at $18.7 million (Q1 2026), $3.8 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.